Clinical Trial

Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice

Completed
View on ClinicalTrials.gov →
Summary
The objective of this study is to evaluate LDL-C reduction over time among individuals initiating alirocumab 150 mg compared with inclisiran in routine clinical practice. The study will leverage observational data reflective of routine care and apply contemporary methods in target trial emulation and causal inference to estimate comparative treatment effects.
Protocol Amendment History 2 changes
critical Trial completed 2026-07-10
notable Enrollment increased: 124 -> 996 participants 2026-07-10
Trial Details
NCT Number NCT07615166
Lead Sponsor Sanofi
Conditions Atherosclerotic Cardiovascular Disease
Enrollment 996 participants
Start Date 2025-05-22
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-09